Pepgen reports first quarter 2023 financial results and recent corporate developments

– phase 2 open-label connect1-edo51 study expected to be initiated in canada in the first half of 2023 – – potentially registration-directed, randomized, double-blind, placebo-controlled phase 2 connect2-edo51 multinational study expected to be initiated in the second half of 2023 – – phase 1 randomized, double-blind, placebo-controlled freedom-dm1 study expected to be initiated in the first half of 2023 – – ended first quarter 2023 with cash, cash equivalents, and investments of $165.4 million; cash runway expected into 2025 – boston, may 11, 2023 (globe newswire) -- pepgen inc. (nasdaq: pepg), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today reported financial results for the first quarter ended march 31, 2023. “pepgen has had an impressive start to 2023 and anticipates a meaningful year ahead.
PEPG Ratings Summary
PEPG Quant Ranking